Last Call for canSERV Third Open Call Funding
Ein Dokument
mehr
Storys zum Thema Krankheit
Event Announcement: VIROFIGHT Hybrid Symposium
Ein DokumentmehrLaunch of canSERV Call for Service Provision – "Training the Next Generation of Cancer Researchers"
Ein Dokumentmehr- 2
Fundació Puigvert validates a new tool capable of selecting the most suitable antibiotic for uncomplicated urinary tract infections within 45 minutes.
Ein Dokumentmehr - 2
Record financing rounds at the Munich biotech hub
Ein Dokumentmehr canSERV relaunches Open Call for Service Provision
Ein DokumentmehrPress release: STADA continues strong growth journey in the first half of 2024
Ein DokumentmehrcanSERV to Accelerate Your Cancer Research - 2 Calls for Service Provision Open
2 Dokumentemehr- 4
Sysmex’s PA-100 AST System Wins One of the UK’s Biggest Science Prizes
Ein Dokumentmehr Press release: Alvotech and STADA add to strategic alliance through denosumab partnership
Alvotech and STADA add to strategic alliance through denosumab partnership - STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central Asia and the Middle ...
Ein DokumentmehrPress release: STADA welcomes CHMP positive opinion on extending indication for Kinpeygo
STADA welcomes CHMP positive opinion on extending indication for Kinpeygo - The CHMP adopted a positive opinion recommending a change to the terms of the marketing authorization of Kinpeygo for the treatment of adults with primary immunoglobulin A, now covering patients with a UPCR of ≥0.8 g/g - ...
Ein DokumentmehrPress release: Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK - Bio-Thera and STADA have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® ...
Ein DokumentmehrcanSERV invites applications for "Revolutionising Cancer Patient Care"
Ein Dokumentmehr- 3
canSERV invites applications for "Revolutionising Cancer Patient Care"
Ein Dokumentmehr LAST CHANCE: canSERV Second Open Call for Cancer Research Service Provision
Ein Dokumentmehr- 3
canSERV Initiative: EU Consortium Launches Groundbreaking Call to Accelerate Cancer Research
Ein Dokumentmehr Press release: STADA continues with double-digit sales and profit growth in 2023
Ein DokumentmehrLeipzig Tourismus und Marketing GmbH
5Pioneering Heart Surgery and Medical Congresses in Leipzig
Ein DokumentmehrStrengthening the Direct Sales and Service System for Business Expansion in Italy
Ein DokumentmehrPress release: STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara - Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within ...
Ein Dokumentmehr- 3
EU Provides 1 Mio. to Researchers to Advance Personalised Oncology
Ein Dokumentmehr canSERV Releases Open Call for Transnational Service Provision
Ein Dokumentmehr- 2
Press release : People with Parkinson’s experience variations in effects of oral medicines, but lack advice, international survey reveals
Ein Dokumentmehr - 2
Press release: STADA's excellent results in H1 2023 indicate a record annual profit of €1 bn, driven by Consumer Healthcare and Specialty
Ein Dokumentmehr - 5
Press Release - hubergroup India expands its support for rural healthcare
Ein Dokumentmehr Free Access to Cancer Research Services - canSERV 1st Call for Proposals
Ein DokumentmehrInnovation and Start-up Center Biotechnology (IZB) welcomes Invitris
Ein DokumentmehrPress release: EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) - Partners Alvotech and STADA have marketing authorization application (MAA) for ustekinumab accepted for filing by the European Medicines Agency (EMA) ...
Ein DokumentmehrPress release: Alvotech and STADA Broaden Access to Adalimumab Biosimilar in Europe
Alvotech and STADA Broaden Access to Adalimumab Biosimilar in Europe - Launches in Belgium, Bulgaria, Croatia, Czech Republic, Latvia, Romania, and Slovenia, increasing availability of high-concentration, citrate-free adalimumab in Europe - Follows initial introduction of adalimumab in ninecountries: ...
Ein DokumentmehrInnovation and Start-Up Center for Biotechnology (IZB) welcomes new start-up Origin.Bio
Ein Dokumentmehr
12Nächste